Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07232849
PHASE2

A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combined with other antitumor therapies in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.

Official title: Study on Efficacy and Safety of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-12-04

Completion Date

2028-12

Last Updated

2025-12-12

Healthy Volunteers

No

Conditions

Interventions

DRUG

HRS-4508 tablet

PartA :HRS-4508 tablet fixed dose+SHR-A1811 fixed dose PartB:HRS-4508 tablet fixed dose + Adebrelimab Injection fixed dose PartC:HRS-4508 tablet fixed dose +SHR-A1811 fixed dose + Adebrelimab Injection fixed dose

Locations (2)

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China

Zhejiang Tumor Hospital

Hangzhou, Zhejiang, China